Lek Powers up Cell Culture Plant
Menges - Lek Pharmaceuticals inaugurated a new manufacturing plant (PORT1) for the production of biopharmaceuticals - such as human proteins for therapeutic applications - near the Slovenian capital Lubljana in Menges in early February.
The new cell-culture facility, the first of its kind in Slovenia and Eastern Europe according to Lek, was built in two years at an investment of more than Euro18 million. Lek, a member of the Novartis Group, will develop, manufacture and market biophar-maceuticals through its own business units as well as through the Sandoz Group. The new facility created more than 20 new jobs for experts in the fields of microbiology, biology, chemistry and pharmaceuticals. With its two 200-litre perfusion bioreactors the new plant's production capacity has been designed to ensure production levels allowing global product marketing.